FindTrial
Sign In

Construction and Verification of Intelligent Prediction System of Pathological Immune Markers Based on Deep Learning

Construction and Verification of Intelligent Prediction System of Pathological Immune Markers Based on Deep Learning

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200065689
Enrollment
Unknown
Registered
2022-11-11
Start date
2022-07-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Interventions

High-AR expression level group:none
Low-AR expression level group:none

Sponsors

Southeast University affiliated Zhongda Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. >18 years old, no cognitive dysfunction; 2. Pathological diagnosis of prostate adenocarcinoma; 3. Complete clinical and pathological data.

Exclusion criteria

Exclusion criteria: 1. Accompanied by other malignant tumors; 2. Preoperative radiotherapy and chemotherapy.

Design outcomes

Primary

MeasureTime frame
AR expression level;—

Countries

China

Contacts

Public ContactChen Ming

Southeast University affiliated Zhongda Hospital

mingchenseu@126.cn+86 13913009977

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026